title: [Intravesical chemotherapy for superficial bladder tumors].
abstract: Intravesical chemotherapy is one of the most effective treatments for superficial bladder tumors. Recent progress in the development of chemotherapeutic agents has provided a variety of compounds of potential benefit for intravesical administration in cases of superficial bladder tumors, including thio-TEPA, MMC, carboquone, adriamycin, FT-207, cytosine arabinoside and bleomycin, and the in therapeutic effectiveness has been reported. We selected adriamycin, because it is considered suitable for intravesical instillation. A 68% effectiveness has been experienced for instillation repeated six to nine times (adriamycin 50 mg/normal saline 30 ml) and side effects occurred in 23% of patients. Intravesical chemotherapy has also been attempted to prevent recurrence after conservative therapy but these modalities still seem to need further study.
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001761:Bleomycin / Q000008:administration & dosage; D002225:Carbazilquinone / Q000008:administration & dosage; D003561:Cytarabine / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D008297:Male; D016685:Mitomycin; D008937:Mitomycins / Q000008:administration & dosage; D005641:Tegafur / Q000008:administration & dosage; D013852:Thiotepa / Q000008:administration & dosage; D001743:Urinary Bladder; D001749:Urinary Bladder Neoplasms / Q000188:drug therapy*
chemical_list: D008937:Mitomycins; D003561:Cytarabine; D001761:Bleomycin; D005641:Tegafur; D002225:Carbazilquinone; D016685:Mitomycin; D004317:Doxorubicin; D013852:Thiotepa